FDA should not authorize marketing flavored ZYN nicotine pouches as modified risk products because Swedish Match failed to provide evidence specific to ZYN demonstrating that they will benefit the health of the population, including youth

FDA should not authorize marketing flavored ZYN nicotine pouches as modified risk products because Swedish Match failed to provide evidence specific to ZYN demonstrating that they will benefit the health of the population, including youth

My colleagues at UCSF and Stanford have submitted this public comment to FDA opposing its approval of Swedish Match (owned by Philip Morris International) claim that ZYN is less dangerous (PDF). The TPSAC tracking number is mk4-k6rg-rvku and the general docket tracking number is mk5-q1p5-yauh on Regulations.gov. Here is the comment: FDA’s should not authorize the marketing of 20 flavored ZYN nicotine pouches with the modified risk claim, “Using …